Higher-Dose eye shot tested to tame blinding eye disease
NCT ID NCT07434713
Summary
This study is observing how well a higher-dose version of an existing eye injection (aflibercept 8mg) works in the first two months for people with 'wet' age-related macular degeneration (AMD). Researchers will track how quickly fluid in the back of the eye decreases and if vision improves during this early treatment phase. The goal is to see if this early response can help predict how many injections a patient might need over a full year to keep the disease under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dept. of Ophthalmology, University Hospital, Inselspital
RECRUITINGBern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.